Harvard Bioscience, Inc. (HBIO)Healthcare | Medical Instruments & Supplies | Holliston, United States | NasdaqCM
7.93 USD
+0.03
(0.380%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.93 |
Hot Take ↕ | Aug. 22, 2026, 2:06 a.m. EDT
The immediate outlook remains neutral due to a lack of clear directional edge, despite a recent bounce off the lows. While the price has recovered significantly from the 52-week low, the underlying business fundamentals are severely compromised. The company is reporting negative profit margins and negative return on equity, indicating that the core operations are currently destroying value rather than generating it. This financial distress is compounded by a catastrophic multi-year price trajectory, which has erased over 80% of shareholder value since the start of the observation window. Although the trailing twelve months show some revenue growth, the persistent losses and the fact that the most recent annual return was still negative suggest that the market has not yet recognized a sustainable turnaround. With no dividend to provide income and a balance sheet showing significant debt relative to equity, the investment case relies entirely on a speculative bet on future operational efficiency that has not yet been proven by earnings. The statistical forecast offers only a weak lean upward, which is insufficient to overcome the fundamental risks. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.029976 |
| AutoETS | 0.044174 |
| AutoARIMA | 0.044175 |
| MSTL | 0.051807 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.031 |
| Excess Kurtosis | 0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 595.929 |
| Revenue per Share | 19.639 |
| Market Cap | 36,099,776 |
| Forward P/E | 12.29 |
| Beta | 1.49 |
| Profit Margins | -11.86% |
| Website | https://www.harvardbioscience.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.61224484 |
| Address1 | 84 October Hill Road |
| Address2 | Suite 10 |
| All Time High | 109.93176 |
| All Time Low | 2.8 |
| Ask | 10.24 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 20,770 |
| Average Daily Volume3 Month | 18,530 |
| Average Volume | 18,530 |
| Average Volume10Days | 20,770 |
| Beta | 1.49 |
| Bid | 7.92 |
| Bid Size | 3 |
| Book Value | 1.63 |
| City | Holliston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.93 |
| Current Ratio | 1.874 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.0 |
| Day Low | 7.9101 |
| Debt To Equity | 595.929 |
| Display Name | Harvard Bioscience |
| Earnings Call Timestamp End | 1,786,449,600 |
| Earnings Call Timestamp Start | 1,786,449,600 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 7,370,000 |
| Ebitda Margins | 0.08392999 |
| Enterprise To Ebitda | 10.014 |
| Enterprise To Revenue | 0.841 |
| Enterprise Value | 73,802,776 |
| Eps Current Year | -0.38 |
| Eps Forward | 0.645 |
| Eps Trailing Twelve Months | -2.33 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 508 429 5732 |
| Fifty Day Average | 6.3802 |
| Fifty Day Average Change | 1.5497999 |
| Fifty Day Average Change Percent | 0.24290773 |
| Fifty Two Week Change Percent | 61.224483 |
| Fifty Two Week High | 9.4 |
| Fifty Two Week High Change | -1.4699998 |
| Fifty Two Week High Change Percent | -0.15638296 |
| Fifty Two Week Low | 3.8 |
| Fifty Two Week Low Change | 4.13 |
| Fifty Two Week Low Change Percent | 1.0868422 |
| Fifty Two Week Range | 3.8 - 9.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 985,012,200,000 |
| Float Shares | 3,556,443 |
| Forward Eps | 0.645 |
| Forward P E | 12.294574 |
| Free Cashflow | 5,303,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 316 |
| Fullday Change | 0.0299997 |
| Fullday Change Percent | 0.379743 |
| Fullday Price | 7.93 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.58158 |
| Gross Profits | 51,067,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09395 |
| Held Percent Institutions | 0.4337 |
| Implied Shares Outstanding | 4,552,305 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,619,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts. |
| Long Name | Harvard Bioscience, Inc. |
| Market | us_market |
| Market Cap | 36,099,776 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_598656 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -10,412,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 35,917,686 |
| Number Of Analyst Opinions | 1 |
| Open | 8.0 |
| Operating Cashflow | 651,000 |
| Operating Margins | -0.029040001 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.31 |
| Phone | 508 893 8999 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.93 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 7.9 |
| Price Eps Current Year | -20.868422 |
| Price Hint | 2 |
| Price To Book | 4.865031 |
| Price To Sales Trailing12 Months | 0.41112173 |
| Profit Margins | -0.11858 |
| Quick Ratio | 0.847 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0299997 |
| Regular Market Change Percent | 0.379743 |
| Regular Market Day High | 8.0 |
| Regular Market Day Low | 7.9101 |
| Regular Market Day Range | 7.9101 - 8.0 |
| Regular Market Open | 8.0 |
| Regular Market Previous Close | 7.9 |
| Regular Market Price | 7.93 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 20,638 |
| Return On Assets | 0.01575 |
| Return On Equity | -0.89949 |
| Revenue Growth | 0.111 |
| Revenue Per Share | 19.639 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,552,305 |
| Shares Percent Shares Out | 0.0128999995 |
| Shares Short | 58,827 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 56,015 |
| Short Name | Harvard Bioscience, Inc. |
| Short Percent Of Float | 0.013099999 |
| Short Ratio | 3.61 |
| Source Interval | 15 |
| State | MA |
| Symbol | HBIO |
| Target High Price | 7.5 |
| Target Low Price | 7.5 |
| Target Mean Price | 7.5 |
| Target Median Price | 7.5 |
| Total Cash | 6,503,000 |
| Total Cash Per Share | 1.429 |
| Total Debt | 44,206,000 |
| Total Revenue | 87,808,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.13825 |
| Two Hundred Day Average Change | 1.79175 |
| Two Hundred Day Average Change Percent | 0.29189914 |
| Type Disp | Equity |
| Volume | 20,638 |
| Website | https://www.harvardbioscience.com |
| Zip | 1,746 |